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Chagas disease, caused by Trypanosoma cruzi, is the main cause of dilated cardiomyopathy in the
Americas. Antiparasitic treatment mostly relies on benznidazole (Bzl) due to Nifurtimox shortage or
unavailability. Both induce adverse drug effects (ADE) of varied severity in many patients, leading to
treatment discontinuation or abandonment. Since dosage may inﬂuence ADE, we aimed to assess Bzl
efﬁcacy in terms of parasiticidal and anti-inﬂammatory activity, using doses lower than those previously
reported. BALB/c mice infected with the T. cruzi RA strain were treated with different doses of Bzl.
Parasitaemia, mortality and weight change were assessed. Parasite load, tissue inﬁltrates and inﬂam-
matory mediators were studied in the heart. Serum creatine kinase (CK) activity was determined as a
marker of heart damage. The infection-independent anti-inﬂammatory properties of Bzl were studied in
an in vitro model of LPS-treated cardiomyocyte culture. Treatment with 25 mg/kg/day Bzl turned
negative the parasitological parameters, induced a signiﬁcant decrease in IL-1b, IL-6 and NOS2 in the
heart and CK activity in serum, to normal levels. No mortality was observed in infected treated mice.
Primary cultured cardiomyocytes treated with Bzl showed that inﬂammatory mediators were reduced
via inhibition of the NF-kB pathway. A Bzl dose lower than that previously reported for treatment of
experimental Chagas disease exerts adequate antiparasitic and anti-inﬂammatory effects leading to
parasite clearance and tissue healing. This may be relevant to reassess the dose currently used for the
treatment of human Chagas disease, aiming to minimize ADE.
© 2015 Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chagas disease is caused by infection with the obligate intra-
cellular protozoan parasite Trypanosoma cruzi. This disease is
endemic throughout Central and South America, representing a
major public health problem. The disease is characterized by an
acute phase with high parasitaemia and variable symptoms,
including acute myocarditis, meningoencephalitis or generalized
infection symptoms (hepatosplenomegaly). This is followed by a
chronic phase that may remain asymptomatic during the whole life
or develop into serious digestive or cardiac alterations, which are
found in about 30% of infected individuals and may lead to dilated
cardiomyopathy (Teixeira et al., 2002).aguay 2155, piso 12, Buenos
.
half of Australian Society for ParaThe disease is currently treated with benznidazole (Bzl) (N-
benzyl-2-nitroimidazole acetamide), a drug known to reduce
parasite burden during acute and early chronic infection (Coura,
2009). During the chronic phase, the effect of Bzl is more contro-
versial, although some reports have shown that individuals treated
with Bzl and evaluated decades after the initial infection acquire
signiﬁcant protection from progression of heart pathology (Viotti
et al., 2006; Fabbro et al., 2007). Although Bzl has been used in
clinical settings, its mechanisms of action have not been fully
elucidated yet (Maya et al., 2007). However, several studies have
suggested that Bzl treatment should still be recommended at late
phases of Chagas disease to prevent progression, regardless of the
lack of complete parasite clearance (Garcia et al., 2005; Sosa-Estani
and Segura, 2006; Viotti et al., 2006). Indeed, there is a general
premise that etiological treatment contributes to reducing parasite
load and rearranging the host immune response, leading to a
balanced inﬂammatory response, which is crucial to control Chagas
disease morbidity (Garcia et al., 2005; Viotti et al., 2006).sitology. This is an open access article under the CC BY-NC-ND license (http://
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phagocytic capacity and cytokine proﬁle of leukocytes from Chagas
disease patients in the indeterminate and cardiac phases, both
before and one year after Bzl treatment. Their ﬁndings highlighted
that Bzl treatment contributes to an overall immunomodulation in
the indeterminate phase and induces a broad change of the im-
mune response in patients in the cardiac phase, eliciting an intri-
cate phenotypic/functional network compatiblewith beneﬁcial and
protective immunological events. However, Bzl contains a nitro
group linked to an imidazole whereby unwanted side effects are
common. The most important adverse reactions observed with Bzl
are cutaneous reactions (allergic dermatitis) (Perez-Molina et al.,
2009), digestive intolerance, polyneuritis, bone marrow depres-
sion, toxic hepatitis (Viotti et al., 2009), peripheral neuropathy and
angioedema (Miller et al., 2015). These side effects, which force
about 10% of patients to suspend the treatment, represent the main
disadvantage of Bzl treatment. In addition, Hasslocher-Moreno
et al. (2012) showed that up to 26% of patients treated with Bzl
during the chronic phase develop skin reactions and that some
show gastrointestinal (10%) and/or neurological (around 5%) dis-
orders. Nevertheless, the incidence of adverse reactions has been
insufﬁciently reported, making it difﬁcult to interpret the safety
proﬁle of Bzl. Current evidence supports the treatment of adults
without advanced cardiac disease or signiﬁcant morbidity using
either Bzl or nifurtimox, the other drug available (Jackson et al.,
2010). Nifurtimox is associated with gastrointestinal and neuro-
psychiatric side effects in nearly all patients, only half of whom can
tolerate the full treatment course (Priotto et al., 2009). Bzl is better
tolerated, but due to intermittent medication shortages and drug-
induced rash including StevenseJohnson syndrome, many pa-
tients fail to complete the treatment. Although, as stated above, it
has been proposed that Bzl is usually better tolerated than Nifur-
timox, Rojo et al. (2014) have recently reported about the contro-
versial toxicity of both drugs. However, Maya et al. (2007) found no
signiﬁcant adverse drug effects in a large series of patients treated
with these drugs. Upon infection, the parasite is able to invade and
multiply within diverse cell types, including macrophages. The
acute phase of infection is characterized by the presence of para-
sites in the host bloodstream and diverse tissues. A crucial step in
cardiomyopathy is the inﬁltration of monocytes and their differ-
entiation into macrophages. These cells may either inhibit T. cruzi
multiplication or provide a favourable environment in which it can
divide and be disseminated to other sites within the body
(Tanowitz et al., 1992; Penas et al., 2015). Besides, there is sub-
stantial evidence showing that cardiac tissue, an important target
of T. cruzi infection, produces marked amounts of pro-inﬂammatory
cytokines, chemokines and enzymes, including inducible nitric
oxide synthase (NOS2) and metalloproteinases, resulting in
inﬂammation and cardiac remodelling in response to parasite
infection (Penas et al., 2013).
In addition to its antiparasitic activity, Bzl exerts immunomod-
ulatory effects in macrophages stimulated with lipopolysaccharide
(LPS) and treated with a high concentration of Bzl (1 mM) (Piaggio
et al., 2001). These immunomodulatory effects of Bzl have also been
described in LPS-challenged mice pre-treated with high doses of
Bzl, showing the ability of Bzl to increase survival and decrease
serum levels of IL-6 and TNF-a in C57BL/6 mice (Pascutti et al.,
2004). The fact that components of T. cruzi as
glycosylphosphatidylinositol-anchored mucin-type glycoproteins
and glycoinositolphospholipids through the toll-like receptors
TLR2/TLR6 and TLR4, respectively, induce proinﬂammatory cyto-
kines (Junqueira et al., 2010) validates the use of LPS in studies that
explore the mechanism of action of Bzl.
In the present study, we considered the administration of doses
of Bzl lower than those usually used in experimental models ofT. cruzi infection, to evaluate its parasiticidal as well as immuno-
modulatory effects, to minimize the adverse side reactions that
usually lead to cessation of therapy.
2. Materials and methods
2.1. In vivo model: mice and infection
Mice used in this study were bred and maintained in the animal
facility at the Instituto de Investigaciones en Microbiología y Par-
asitología Medica, Universidad de Buenos Aires e CONICET. All
procedures carried out with mice were approved by the Institu-
tional Committee for the Care and Use of Laboratory Animals
(CICUAL, Facultad de Medicina de la Universidad de Buenos Aires)
and are in accordance with guidelines of the Argentinean National
Administration of Medicines, Food and Medical Technology
(ANMAT), Argentinean National Service of Sanity and Agrifoods
Quality (SENASA) and also based on the US NIH Guide for the Care
and Use of Laboratory Animals. Eight-weeks old BALB/c male mice
(7 per group) were infected intraperitoneally with 500 bloodstream
trypomastigotes of the lethal RA (pantropic/reticulotropic) strain of
T. cruzi, (DTU VI) as previously described (Celentano and Gonzalez
Cappa, 1993; Zingales et al., 2009). Benznidazole (Abarax®, ELEA,
Argentina. PubChem Compound Database CID¼ 31593), suspended
in corn oil, was administered orally at 10, 25 and 100mg/kg/day, for
30 consecutive days. The groups received the following treatments:
Group 1 ¼ Corn oil, Group 2 ¼ Bzl 10 mg/kg/day, Group 3 ¼ Bzl
25mg/kg/day, Group 4¼ Bzl 100 mg/kg/day, Group 5¼ Uninfected,
untreated. Treatment started soon after the detection of parasites in
blood, which occurred at day 7 post-infection (p.i.).
Parasitaemia of infected untreated mice (Group 1) peaks be-
tween day 10 and 13. Therefore, they were sacriﬁced at the time
when they began to show signs of cachexia, since they did not
survive after 15 days. Mice of Groups 2 through 5 were sacriﬁced at
day 55 p.i. Each experiment was carried out three times.
2.2. Parasitaemia and survival
Presence of parasites in blood was evaluated by micro-
hematocrit method (Feilij et al., 1983). Parasitaemia was analysed
using Pizzi's technique modiﬁed by Brener (1962) every three to
seven days, and survival was observed daily, until the end of the
experiment. Parasitaemia was expressed as parasites per millilitre
of blood.
2.3. Histopathological studies
Hearts from T. cruzi infected untreated and benznidazole-
treated infected mice (25 mg/kg/day), were ﬁxed in formalin and
embedded in parafﬁn. Six non-contiguous sections (5 mm) were cut
and stained with haematoxylin-eosin. Cellular inﬁltrates and the
presence of amastigote nests were examined using a Nikon Eclipse
E600microscope (Nikon Inc.). Images were capturedwith a Spot RT
digital camera. At least thirty random microscopic ﬁelds (400)
were analysed in each microscopic section, using the open source
Image J software (NIH, USA).
2.4. Creatine kinase activity
The activity of CK as amarker heart injury was determined using
commercially available assay kits according to manufacturer's in-
structions (Wiener Lab, Rosario, Argentina). The kit relies on the
reduction of NADPþ and the increase of absorbance measured at
340 nm.
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culture
One-to 3-day old neonatal outbred CF-1 strain mice were
euthanized by decapitation after CO2 exposure, and car-
diomyocytes were obtained as previously described (Hovsepian
et al., 2013).
Each experiment was carried out 3 times with 5 replicates per
group.
2.6. Puriﬁcation of bloodstream trypomastigotes of T. cruzi
Bloodstream trypomastigotes were obtained by cardiac punc-
ture, from euthanized 21-days old male CF-1 mice infected 7 days
previously by intraperitoneal route with 1.0  105 trypomastigotes
of RA strain of T. cruzi, as previously described (Gonzalez Cappa
et al., 1981b; Maggini et al., 2010). Brieﬂy, blood diluted 1:5 in
culture mediumwas centrifuged at 400 g at room temperature and
then left at 37 C for 1 h in a water bath. Trypomastigotes in the
supernatant were essentially devoid of blood cells and platelets
according to microscopic examination. Quantiﬁcation of parasites
was performed with a Neubauer chamber.
2.7. Assay to evaluate the trypanocidal effect of benznidazole
in vitro
Cardiomyocytes were cultured at 37 C under 5% CO2 atmo-
sphere and infected at a 5:1 parasite: cell ratio in six well poly-
styrene plates. After 3 h, the infected cultures were washed ﬁve
times with fresh 1% FCS-DMEM: M-199 medium to remove free
parasites. The infected cells were cultured for 48 h and then treated
with 3, 15 or 75 mM of Bzl, for 72 h. Then, genomic DNA (gDNA) was
obtained and parasitic load in cardiac cells was analysed by quan-
titative real-time PCR (qPCR).
2.8. Assay to evaluate benznidazole effects on inﬂammatory
mediators
Cardiomyocytes in culture were pre-treated for 30 min with Bzl
3, 15 or 75 mM and stimulated with LPS (10 mg/L) from Escherichia
coli O26:B6 (SigmaeAldrich Co) for the indicated period of time.
mRNA and protein extracts were obtained, and RT-qPCR, Western
blot and immunoﬂuorescence analysis were performed (See
below).
2.9. mRNA and gDNA puriﬁcation
Total RNA was obtained from heart tissue homogenates and
from cultured cells using Quickzol reagent (Kalium), treated with
DNAse (Life Technologies) and total RNA was reversed transcribed
using Expand Reverse Transcriptase (Promega Corporation),
following themanufacturer's instructions. gDNAwas obtained from
heart tissue or the cultured cells using phenol-chloroform extrac-
tion (Laird et al., 1991).
2.10. Quantitative real-time polymerase chain reaction (qPCR and
RT-qPCR)
Both qPCR and RT-qPCR were performed using 5X HOT FIREPOL
EVAGREEN qPCR (Solis BioDyne) in an Applied Biosystems 7500
sequence detector. mRNA expressionwas analysed by RT-qPCR. The
parameters were: 52 C for 2 min, 95 C for 15 min, and 40 cycles of
95 C for 15 s, 60 C (for NOS2, IL-6 and 18S rRNA) or 57 C (for IL-
1b) for 30 s and 72 C for 1 min. Expression of 18S rRNA was ana-
lysed in the samples in the same run for normalization.Quantiﬁcation of parasite load in heart tissue or cultured cardiac
cells was performed by qPCR with the primers TCZ (Cummings and
Tarleton, 2003; Duffy et al., 2009). These primers amplify a 146-bp
sequence of the highly repetitive (104 repeats) satellite genomic
DNA. The high number of copies increases the sensitivity of the
technique allowing the detection of less than 1 parasite/ml, which
is deﬁned as parasite equivalents.
Quantiﬁcation was calculated using the comparative threshold
cycle (Ct) method and efﬁciency of the RT reaction (relative quan-
tity, 2DDCt). The replicates were then averaged and fold induction
was determined, considering the value at zero time as 1
(Schmittgen and Livak, 2008).
Primer sequences are shown in Supplementary Information
section.
2.11. Preparation of cytosolic, nuclear and total protein extracts for
Western blot
Heart tissue (100 mg) was homogenized with 300 ml of Buffer A
(See below), or cultured cells werewashedwith PBS and scraped off
the dishes, with 50 ml of the same buffer, and NP-40 (Life Tech-
nologies) was added to reach 0.5% (v/v). After 15 min at 4 C, the
tubes were gently vortexed for 10 s, and cytosolic extracts were
collected by centrifugation at 13,000 g for 90 s. The supernatants
were stored at 20 C (cytosolic extracts), and heart pellets were
resuspended in 100 ml buffer A supplemented with 20% (v/v)
glycerol and 0.4 M KCl, and mixed for 30 min at 4 C. Nuclear
proteins were obtained by centrifugation at 13,000 g for 5 min, and
aliquots of the supernatant (nuclear extracts) were stored
at 80 C.
Total protein extracts were obtained after washing the hearts
with PBS and adding 300 ml of RIPA modiﬁed lysis buffer (See
below), or washing the cultured cells and scraped off the dishes
with 50ul of the same buffer. Then, the tubes were kept on ice for
30minwith swirling and the samples were centrifuged at 7000 g at
4 C for 10 min. The supernatant was stored at 20 C. Protein
concentrations of sera and protein extracts were determined by the
Bradford method using the Bio-Rad Protein Assay (Bio-Rad, USA)
reagent and bovine serum albumin (BSA) (SigmaeAldrich Co.) as a
standard (Kruger, 1994).
2.12. Western blot analysis
Proteins extracts were boiled in Laemmli sample buffer, and
equal amounts of protein (50e100 mg) were separated by 8e12%
SDSePAGE. The gels were blotted onto a Hybond-P membrane (GE
Health-care, Madrid, Spain) and incubated with the following an-
tibodies: anti-NOS2, anti-IkB-a, anti-p65 (Santa Cruz Biotech-
nology, CA, USA), and anti-a-actin (SigmaeAldrich Co). The blots
were revealed by enhanced chemiluminescence (ECL) in an Image
Quant 300 cabinet (GE Healthcare Biosciences, USA) following the
manufacturer instructions. Band intensity was analysed using the
Image J software.
2.13. NO measurement
To determine the amount of NO released into the culture me-
dium, nitrate was reduced to nitrite and measured spectrophoto-
metrically by the Griess reaction (Bryan and Grisham, 2007; Díaz-
Guerra et al., 1996). The absorbance at 540 nm was compared
with a standard curve of NaNO2.
2.14. Immunoﬂuorescence
Myocardial cells grown on round glass coverslips were ﬁxed
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IkBa and NOS2 were determined by immunoﬂuorescence. For this
purpose, rabbit polyclonal IgG anti-NOS2 or IgG anti-IkBa (Santa
Cruz Biotechnology, CA, USA) and FITC-labelled goat anti-rabbit IgG
(SigmaeAldrich Co), were used at 1:200 dilutions (determined by
titration). Cells nuclei were stained with DAPI (300 nM). At least 30
random microscopic ﬁelds (400) and 1000 cells per culture were
acquired using a Spot RT digital camera attached to an Eclipse 600
ﬂuorescence microscope (Nikon Inc., USA).
2.15. Buffer composition
HBSS: (in g/L): 0.4 KCl, 0.06 KH2PO4, 8.0 NaCl and 0.05 Na2HPO4,
pH 7.4.
HBSS Plus (in g/L): HBSS plus 0.14 CaCl2, 0.047 MgCl2, 0.049
MgSO4, 0.35 NaHCO3 and 1.0 D-glucose, pH 7.40.
Buffer A: 10 mmol/L HEPES pH ¼ 7.90, 1 mmol/L EDTA, 1 mmol/
L EGTA,10mmol/L KCl,1 mmol/L DTT, 0.5mmol/L PMSF, 40mg/L
leupeptin, 2 mg/L tosyl-lysyl-chloromethane, 5 mmol/L NaF,
1 mmol/L NaVO4, 10 mmol/L Na2MoO4.
RIPA modiﬁed lysis buffer: 150 mM NaCl, 50 mM TriseHCl
(pH ¼ 7.40), 1% Triton X-100, 1 mM EDTA, 1 mM PMSF; 2.5 g/L
Protease Inhibitor Cocktail (Sigma Aldrich), 1 mMNa3VO4, 1 mM
NaF.2.16. Statistical analysis
Data are expressed as mean of 3 independent
experiments ± SEM for each treatment (7 mice or 5 culture repli-
cates/group). The KaplaneMeier method and ManteleCox test
were used to compare survival curves of the studied groups. One-
way ANOVA was used to analyse the statistical signiﬁcance of the
differences observed between the infected, treated or untreated
groups. The Dunnet post-hoc test was performed to compare
treated groups against the control group (T. cruzi or LPS according
to the experimental setting). Differences were considered statisti-
cally signiﬁcant when P < 0.05. All analyzes were performed using
the Prism 5.01 Software (GraphPad, USA).
3. Results
3.1. Benznidazole is effective as an antiparasitic drug at a dose
lower than the usual one
BALB/c mice were infected with 500 trypomastigotes of the
virulent and lethal RA T. cruzi strain by the intraperitoneal route to
assess whether Bzl has effective trypanocidal activity at concen-
trations lower than those usually used in experimental models
(100mg/kg/day). The presence of parasites in blood, evaluated from
day 5 post-infection (p.i.) by the microhematocrit method, became
apparent on day 7 p.i. in all experimental groups, reaching quan-
tiﬁable values by day 9 p.i. (0.0315  106 ± 0.003 parasites/mL,
n ¼ 3), with a maximum on day 13 (0.561  106 ± 0.169 parasites/
mL, n ¼ 3). Different groups were daily treated with 10 mg/kg/day
(low dose), 25 mg/kg/day (mid dose) or 100 mg/kg/day (high dose)
of Bzl, respectively, from day 7 p.i. Treatment with 25 mg/kg/day of
Bzl was almost as effective in its trypanocidal action as the usual
dose of 100 mg/kg/day on day 13 (mid dose vs high dose,
0.094 ± 0.020 vs 0.00± 0.00 parasites/mL, n¼ 3, P< 0.001) (Fig.1A).
In contrast, the treatment with the low dose showed no antipara-
sitic effect on day 13 p.i. (infected vs infected treated with low dose,
0.561  106 ± 0.169 parasites vs 0.581  106 ± 0.252 parasites/mL,
n ¼ 5, P < 0.05). A decrease in weight was observed in the infected
untreated mice and mice treated with low-dose Bzl in comparisonwith uninfected controls. Moreover, the body weight of mice
treated with mid and high Bzl doses remained unchanged
throughout the study (Fig. 1B). Consistently with the increase of
parasitaemia, infected untreated mice did not survive longer than
day 15 p.i., whereas mice treated with 25 mg/kg/day of Bzl had
survival rates similar to those treated with 100 mg/kg/day (Fig. 1C).
3.2. Benznidazole clears tissue parasite load, attenuates
inﬂammatory reaction and normalizes creatine kinase activity in
T. cruzi-infected mice
Given that the effects in reducing parasitaemia and maintaining
survival of the dose of 25 mg/kg/day were similar to those of the
dose of 100 mg/kg/day, we investigated the presence of parasites
and inﬂammatory reaction in the heart. While T. cruzi-infected
untreated mice showed signiﬁcant numbers of amastigote nests in
sinuses and ventricles, as well as inﬂammatory reaction associated
with them, mice treated with 25 mg/kg/day showed neither in-
ﬂammatory cells nor amastigote nests (Fig. 2A). To further conﬁrm
that T. cruzi-infected Bzl-treated mice were devoid of parasites in
the heart, qPCR using TCZ primers was performed after gDNA
extraction from this tissue. No gDNA ampliﬁcation was obtained in
the hearts of mice treated with 25 mg/kg/day (Fig. 2B).
We measured changes in serum CK activity as a biochemical
marker of heart injury upon infection. A signiﬁcant increase in the
level of CK activity on day 15 p.i. was observed in infected mice in
comparison with uninfected untreated control mice (uninfected vs
infected: 0.448 ± 0.116 vs 1.368 ± 0.149, n ¼ 3, P < 0.0001).
Moreover, 30 days after Bzl treatment with 25 mg/kg/day, CK levels
dropped to values found in control mice, suggesting that tissue
injury was precluded by Bzl (0.240 ± 0.041, n ¼ 3, P < 0.0001)
(Fig. 2C).
3.3. NOS2 and pro-inﬂammatory cytokines are inhibited by
benznidazole in hearts of T. cruzi-infected mice
Previous studies have shown that Bzl treatment modulates pro-
inﬂammatory cytokines in vitro models of LPS stimulation (Revelli
et al., 1999; Piaggio et al., 2001) and an in vivo model of sepsis
(Pascutti et al., 2004; Ronco et al., 2011). To determine whether Bzl
modulates inﬂammatory mediators in experimental acute Chagas
disease, T. cruzi-infected mice were treated with 25 mg/kg/day of
Bzl, the lowest antiparasitic dose. The hearts of RA-infected mice
expressed considerable amounts of IL-1b mRNA (uninfected vs.
infected, 0.725 ± 0.275 vs 10.370 ± 4.502, n ¼ 3, P < 0.001) and IL-6
mRNA (uninfected vs. infected, 0.849 ± 0.301 vs 13.260 ± 2.873
n¼ 3, P < 0.0001) measured by RT-qPCR on day 15 p.i., before death
(Fig. 3A). Furthermore, infected mice treated with Bzl for 30 days
showed a marked decrease in the cardiac levels of both IL-1b
(0.690 ± 0.136, n ¼ 3, P < 0.05) and IL-6 (0.549 ± 0.135, n ¼ 3,
P < 0.0001) mRNA expression. Fig. 3B shows that the same applied
to NOS2 mRNA (uninfected vs infected: 1.107 ± 0.475 vs
4.369 ± 0.845; infected treated: 1.052 ± 0.202, n ¼ 3, P < 0.05) and
protein expression determined at the same times (uninfected vs
infected: 0.394 ± 0.240 vs 1.718 ± 0.406; infected treated:
0.690 ± 0.104, n ¼ 3, P < 0.05).
3.4. Trypanocidal effect of benznidazole on primary cultures of
infected cardiomyocytes
To assess the parasiticidal effect of low concentrations of Bzl
in vitro, primary cardiomyocyte cultures were infected with T. cruzi
at a 5:1 parasite: cell ratio and incubated with different concen-
trations of Bzl for 72 h. Fig. 4A shows that 75 mM Bzl signiﬁcantly
reduced the parasite load in comparison with untreated cells.
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to almost negligible levels when measured as equivalent parasites
per 50 ng total gDNA by qPCR, in this period of time. Cell viability
was studied after treatment with different concentrations of Bzl in
cardiomyocytes.We found that cell viability was not affected by any
of the concentrations of Bzl tested (Fig. 4B).3.5. Benznidazole inhibits inﬂammatory mediators in cultured
cardiomyocytes
We have previously described that T. cruzi infection produces an
intense inﬂammatory response, which is critical for the control of
the evolution of Chagas disease. In this regard, we determined the
expression of typical inﬂammatory markers like NOS2 with high
levels of nitric oxide (NO) or inﬂammatory cytokines like IL-1b, IL-6
and TNFa in infected cardiomyocytes (Hovsepian et al., 2011, 2013).
Other authors have previously reported the inhibitory effect of Bzl
on the production of NOS2-dependent NO by RAW 264.7 macro-
phages at high concentrations ranging from 0.1 mM to 1 mM
(Revelli et al., 1999). With the aim to dissociate the antiparasitic
effect of Bzl from its anti-inﬂammatory properties, the ability of the
lowest doses of Bzl to inhibit inﬂammatory mediators were
assessed in cultured cardiomyocytes treated with Bzl and stimu-
lated with LPS. When the cells were pre-incubated with 15 mM Bzl
(a concentration rendering parasite DNA almost undetectable by
qPCR) and stimulatedwith 10mg/L of LPS, a signiﬁcant inhibition of
both NOS2 expression (Fig. 5A and B) and NOS2-dependent NO
production was observed (Fig. 5A). Moreover, decreased IL-1b and
IL-6 mRNA levels were found after 4 h, as shown by RT-qPCR
(Fig. 5C).3.6. Benznidazole at low concentrations also inhibits the NF-kB
pathway
To assess whether Bzl inhibits inﬂammatory mediators through
inhibition of the NF-kB pathway, after an inﬂammatory stimulus,
cardiomyocyte cultures were pre-treated with Bzl and incubated
for 30, 60 or 120 min with LPS. The speciﬁc inhibitor of this tran-
scription factor, IkBa, as well as the p65-NF-kB subunit, diminished
in the cytoplasmic fraction after 30 min of LPS incubation as
assessed byWestern blot, conﬁrming the activation of this pathway
(0.111 ± 0.006 and 0.403 ± 0.029 respectively, n ¼ 3, P < 0.0001).
Signiﬁcantly, pre-treatment with 15 mMBzl impaired both IkBa and
p65 disappearance from the cytosolic fraction (0.650 ± 0.028 and
0.971± 0.064 respectively, n¼ 3, P< 0.0001) (Fig. 6A). This suggests
that this trypanocidal drug exerts regulation through the NF-kB
pathway at a concentration lower than that previously reported
(Piaggio et al., 2001). The effect of low concentrations of Bzl was
conﬁrmed by immunocytochemistry. Detection of IkBa by immu-
noﬂuorescence showed that it disappeared from the cytoplasm
when NF-kB was activated by LPS. Moreover, IkBa levels were
restored to values similar to those in unstimulated cells when
cardiomyocytes were pre-treated with Bzl before LPS stimulation
(Fig. 6B).
4. Discussion
The current treatment for Chagas disease with Bzl is effective to
cure the infection in the acute phase, limiting the incapacity and
preventing morbidity and mortality (Rassi et al., 2009, 2011).
However, this treatment has serious limitations, such as the side
effects exhibited by some patients (Castro et al., 2006). These
include organic manifestations indicative of systemic toxicity such
Fig. 2. Benznidazole clears tissue parasite load, attenuates inﬂammatory reaction and normalizes creatine kinase activity in T. cruzi-infected mice. Cardiac parasite load and in-
ﬂammatory reaction was analysed in histological sections of the hearts of uninfected mice (left panels), infected mice at 15 d.p.i (centre panels) or infected and Bzl-treated mice
(25 mg/kg/day, right panels) at 55 d.p.i. Inﬂammatory reaction in the sinus of a T. cruzi-infected mouse is shown (Black left-hand arrow). Amastigotes and necrotic myoﬁbers can be
observed. An isolate amastigote nest not surrounded by inﬂammatory reaction is also shown (Green right-hand arrow) (upper centre panel). Preserved architecture of the sinus of a
T. cruzi-infected and Bzl-treated mouse is shown. Neither amastigote nests nor inﬂammatory reaction are observed (upper right panel). Inﬂammatory reaction in the ventricle of a
T. cruzi-infected mouse is observed (black right-hand arrow). Amastigotes (green left-hand arrow) and necrotic myoﬁbers can be observed (lower centre panel). Preserved ar-
chitecture of the sinus and ventricle of a T. cruzi-infected and Bzl-treated mouse are shown. Neither amastigote nests nor inﬂammatory reaction is observed. Notice the preserved
architecture of the vascular wall (right panel). Haematoxylin-Eosin stain. Magniﬁcation: 400. Panoramic view of the detailed area: 100. Bar: 100 mm. (A). Heart parasite load was
detected by qPCR of infected mice at 15 d.p.i or infected and Bzl-treated mice (25 mg/kg/day) at 55 d.p.i. (B). CK activity in the sera of T. cruzi-infected mice at 15 d.p.i. or T. cruzi-
infected and Bzl-treated (25 mg/kg/day) mice at 55 d.p.i, was determined as a marker of heart injury (C). Results are expressed as mean of 3 independent experiments (7 mice/
group) ± SEM. ***P < 0.0001 vs T. cruzi-infected mice; ##P < 0.001 vs uninfected control mice. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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bone marrow depression and polyneuropathy. All these symptoms
are evident in the ﬁrst days of treatment and represent a major
threat of Bzl in clinical use with frequent therapy discontinuation
(Rodriques Coura and de Castro, 2002; Castro et al., 2006; Rassi
et al., 2009; Viotti et al., 2009; Pinazo et al., 2013). Thus, ﬁnding
options to enhance the effectiveness of Bzl and to decrease its
adverse effects is very desirable, if we consider that this is the only
antiparasitic treatment currently available in most countries. The
effectiveness of different experimental protocols aiming to modify
the dose of this antiparasitic drug has not been thoroughly tested.
Therefore, in the present study we proposed to test doses lower
than normally used in experimental Chagas disease treatment to
determine the minimal effective dose.
We report for the ﬁrst time that Bzl has parasiticidal properties
in vivo as well as in vitro at doses lower than those previously re-
ported for a highly virulent T. cruzi strain. In addition, treatment
with a lower dose of Bzl was also able to inhibit the expression of
inﬂammatory mediators and tissue inﬂammation.Our results show that, in mice infected with the RA strain of
T. cruzi, the treatment with 25 mg/kg/day of Bzl was as effective as
100 mg/kg/day, the therapeutic dose usually used to cure experi-
mental Chagas disease (de Andrade et al., 1996; Guedes et al., 2011;
Molina-Berríos et al., 2013). This was reﬂected in the rate of survival
after treatment, since no signiﬁcant differences were observed
between the experimental groups using both doses. Moreover, after
treatment with low doses of Bzl, mice regained the weight they had
lost due to infection. An optimal dose of Bzl (25 mg/kg/day) was
associated with the absence of inﬂammatory reaction and tissue
parasite load as measured by qPCR. In this regard, Martins et al.
(2008) have previously reported for an experimental murine
model, that serological and blood parasitological tests for T. cruzi
are less sensitive than tissue qPCR. Thus, our results strongly sug-
gest that this low-dose Bzl treatment is able to clear T. cruzi from
the infected host. In contrast, other research groups argue that only
the optimal dose of 100 mg/kg/day of Bzl confers almost complete
protection against death to infected mice (Toledo et al., 2003;
Assíria Fontes Martins et al., 2015)
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A.C. Cevey et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 12e2218This study was carried out using the T. cruzi RA strain that be-
longs to DTU VI (Zingales et al., 2009). This strain has a wide tissue
tropism and is highly lethal for the mouse (Mirkin et al., 1994).
Besides, susceptibility of this strain to Benznidazole has beenretained upon passage in outbred CF1 mice, since its isolation from
a child with acute Chagas disease, living in an endemic region of
Argentina (Gonzalez Cappa et al., 1981a).
Its high lethality was a desired characteristic, since it allowed us
to test the effectiveness of the parasiticidal treatment with benz-
nidazole at the tested doses. In this regard, as few as 500 parasites
kill all mice in a short time period. Thus, in the present work we
show that untreated mice or mice treated with the lowest dose,
10 mg/kg/day, succumb to infection. On the contrary, mice treated
with 25 mg/kg/day for 30 days and tested 20 days after the end of
the treatment, remained without detectable parasites in blood and
heart, granting effective cure and leading to 100% survival, as the
standard treatment scheme (100 mg/kg/day for 30 days). Thus, in
the context of drug optimization we consider adequate and
necessary to test the efﬁcacy of lower doses, using a T. cruzi strain
already known to be susceptible to the drug.
Molina-Berríos et al. (2013) found that treatment with 30 mg/
kg/day resulted in the parasitological cure of BALB/c mice infected
with 500 bloodstream trypomastigotes with the non-lethal DM28c
(DTU I) after 20 days treatment, beginning on day 2 post-infection.
It must be noted, however, that the advantage of our model is that
the use of a lethal strain grants that, in case of inadequate treat-
ment, mice will die. Also, the fact that the treatment was effective
even when it began after patent parasitaemia was detected (day 7
post-infection), ensures that mice were actually infected which
allowed the comparison in effectiveness between the different
doses tested.
It may be argued that this study was carried out using only one
parasite strain, belonging to a particular DTU. This may raise issues
regarding the effectiveness of such treatment in view of the feasible
appearance of resistance to benznidazole in different strains. It
must be noted, however, that no evidence has been found so far,
regarding the association between a particular DTU and resistance
to benznidazole. Each DTU may include T. cruzi populations ofvaried resistance to this drug (Gruendling et al., 2015). Moreover,
several studies have shown that resistance may arise at the clonal
level if forced by selective drug pressure upon discontinuous
treatment schemes in vivo (Dos Santos et al., 2008), or upon
Fig. 5. Benznidazole inhibits inﬂammatory mediators in cultured cardiomyocytes. Cardiomyocytes were treated with different concentrations of Bzl for 30 min and then with
10 mg/L LPS for 48 h. NOS2 expression was determined by Western blot with a speciﬁc antibody and normalized against a-actin. NO levels were quantiﬁed by the Griess reaction in
culture supernatants (A). Cardiomyocytes were pre-treated with 15 mM Bzl for 30 min and then with 10 mg/L LPS for 48 h. NOS2 expression was detected by immunoﬂuorescence
with a rabbit polyclonal antibody speciﬁc for NOS2 and a secondary FITC-labelled anti-rabbit IgG. Cells nuclei were stained with 300 nM DAPI. Representative microphotographs
(400) are shown (B). Cardiomyocytes were pre-treated with 15 mM Bzl for 30 min and then with 10 mg/L LPS for 4 h. IL-6 and IL-1b mRNA levels were analysed by RT-qPCR and
normalized against 18S rRNA (C). Scale bar: 10 mm. Results are expressed as mean of 3 independent experiments (3 replicates/treatment) ± SEM. *P < 0.05, **P < 0.001, ***P < 0.0001
vs LPS-stimulated cells; #P < 0.05, ##P < 0.001 vs control cells.
A.C. Cevey et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 12e22 19continuous drug pressure in vitro (Mejia et al., 2012). Our results
strongly suggest that emergence of parasite resistance was avoided
with the reduced dose scheme, since no parasites were detected in
blood and heart at least 20 days after treatment cessation.
Therefore, optimization of the treatment schedule is something
that should be considered in the case of human Chagas disease, as
far as new trypanocidal drugs are not available (Alsford et al., 2013).
Our results show that T. cruzi infection stimulates the inﬂam-
matory response in terms of IL-1b and IL-6 mRNA expression and
NOS2 production in the mouse heart. Accordingly, we have previ-
ously described the onset of inﬂammatory response in mice
infected with T. cruzi strains of different lethality (Penas et al., 2013)
and in neonatal cardiac cells stimulated with LPS or infected with
T. cruzi (Hovsepian et al., 2010, 2011). The expression of inﬂam-
matory genes in the heart plays an essential role in organ
dysfunction. In this regard, it has been shown that NOS2 is involved
in the pathogenesis of cardiac diseases (Qian et al., 2001; Goren
et al., 2004). Interestingly, in Chagas disease, NO has been
described as a trypanocidal mediator (Mu~noz-Fernandez et al.,
1992). However, it has also been suggested that excessive release
of NO by inﬂammatory cells would lead to heart failure (Massion
et al., 2003). In this study, we report for the ﬁrst time that a low
dose of Bzl (25 mg/kg/day) is able to inhibit the expression ofproinﬂammatory cytokines and NOS2 expression in a murine
experimental model of T. cruzi infection. Consistently, reduction of
CK activity, a typical marker of heart damage, was also observed. In
this regard, our results are in agreement with those previously
reported by Pereira et al. (2014).
The anti-inﬂammatory properties of this parasiticidal drug had
been previously tested in different experimental models of sepsis
or macrophages stimulated in culture, but not in an experimental
model of Chagas disease. In the liver of septic mice, Bzl decreases
the mRNA and protein expression of TNF-a and NOS2 by inhibition
of NF-kB and MAPK (p-38 and ERK) (Piaggio et al., 2001; Ronco
et al., 2011) provided evidence that Bzl is able to speciﬁcally
inhibit NO production and cytokine release in RAW 264.7 macro-
phages stimulated with LPS and/or IFN-g. Moreover, in RAW 264.7
macrophages stimulated with LPS, Manarin et al. (2010) deter-
mined that treatment with Bzl inhibits IkBa phosphorylation and
hence its degradation, but not IkB kinase a/b phosphorylation,
despite which, Bzl behaves as a broad-range speciﬁc inhibitor of
NF-kB activation, independently of the stimuli tested. Since in those
works high concentrations of Bzl (1 mM) were used in vitro, in the
present work we decided to test the parasiticidal effect of Bzl at
lower doses in isolated cardiomyocytes in culture, infected with the
RA strain of T. cruzi. We determined that 15 mM Bzl was the optimal
Fig. 6. Benznidazole at low concentrations also inhibits the NF-kB pathway. Cardiomyocytes were treated with 15 mM Bzl for 30 min and then with 10 mg/L LPS for 30, 60 or
120 min. IkBa and p65 cytosolic expression were determined by Western blot with speciﬁc antibodies. Protein levels were normalized against a-actin. A representative result out of
3 experiments performed is shown (A). IkBa expression was detected by immunoﬂuorescence with a polyclonal rabbit anti-IkBa antibody and a secondary FITC-labelled anti-rabbit
IgG. Cells nuclei were stained with 300 nM DAPI. Representative microphotographs (400) are shown (B). Scale bar: 10 mm.
A.C. Cevey et al. / International Journal for Parasitology: Drugs and Drug Resistance 6 (2016) 12e2220concentration to reduce the parasite load in infected cells as
measured by qPCR. This ﬁnding led us to study its anti-
inﬂammatory properties knowing the optimal parasiticidal con-
centration. In this case, the test system involved stimulation of the
cells with LPS. Using this approach, we herein demonstrate that,
in vitro, a concentration of Bzl lower than that usually used inhibits
IL-1b and IL-6 mRNA levels in stimulated cardiomyocytes.
Furthermore,15 mMBzl was able to inhibit NOS2 expression and NO
release, in comparison to other studies showing that 1 mM Bzl
impaired LPS induction of macrophage NOS2 gene transcription
(Piaggio et al., 2001; Manarin et al., 2010). Revelli et al. (1999) have
also demonstrated that a high concentration of Bzl down-regulates
NO and cytokines in macrophages stimulated with LPS, suggesting
that it may also alter the balance between pro- and anti-
inﬂammatory responses. Thorough studies have been carried out
in macrophages stimulated with LPS and treated with 1 mM Bzl to
clarify the mechanism whereby the expression of NOS2 and pro-
inﬂammatory cytokines is inhibited (Piaggio et al., 2001; Manarin
et al., 2010). These studies have shown that inhibition of the NF-
kB pathway is responsible for the down-regulation of pro-
inﬂammatory mediators. Our present results show that, in LPS-
stimulated cardiomyocytes, 15 mM Bzl also inhibited this pathway,demonstrating that the anti-inﬂammatory effects of this drug may
be reached at a concentration lower than the one widely reported.
5. Conclusions
In conclusion, this study shows for the ﬁrst time that optimal
effects of Bzl, in terms of parasite clearance from blood and heart
tissue and reduction of inﬂammatory reaction, can be achieved at
doses signiﬁcantly lower than those usually used for the treatment
in an experimental murine model using a highly virulent
benznidazole-susceptible T. cruzi strain. This ﬁnding may be a
relevant for dose optimization in the treatment of acute human
Chagas disease. This is especially true if one considers the number
and varied severity of adverse effects generated by the use of Bzl,
which lead to the abandonment of treatment by a signiﬁcant pro-
portion of patients.
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